Current use of biologicals for the treatment of spondyloarthropathies

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 1, 2001, Pages 85-93

  De Keyser, F ^a   Mielants, H ^a   Veys, E M ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Ankylosing spondylitis; Anti TNF antibodies; Crohn's disease; Etanercept; Infliximab; Psoriatic arthritis; Spondyloarthropathy

Indexed keywords

ADALIMUMAB; ALICAFORSEN; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; ETANERCEPT; INDOMETACIN; INFLIXIMAB; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 4; LENERCEPT; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; METHOTREXATE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; OM 89; PHENYLBUTAZONE; PIROXICAM; PLACEBO; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANKYLOSING SPONDYLITIS; CLINICAL TRIAL; COLON CROHN DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG RESPONSE; DRUG TARGETING; ENTERITIS; ENTHESOPATHY; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; IMMUNOMODULATION; MOUSE; NONHUMAN; PAIN; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; SYNOVITIS; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, MONOCLONAL; ANTIGENS, BACTERIAL; ANTIRHEUMATIC AGENTS; HUMANS; INTERLEUKIN-10; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; SPONDYLARTHROPATHIES; THIONUCLEOTIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035003995     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.1.85     Document Type: Review

References (58)

1. The bowel and spondylarthritis: A clinical approach
2. Bowel inflammation and the spondyloarthropathies
3. The evolution of the spondyloarthropathies in relation to gut histology. I. Clinical aspects
4. Long-term evolution of gut inflammation in patients with spondyloarthropathy
5. Critères de classification des spondyloarthropathies
6. Sulfasalazine in the treatment of spondylarthropathy: A randomized, multicenter, double-blind, placebo-controlled study
7. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Co-operative Study
8. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Verterans Affairs Co-operative Study
9. Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome). A Department of Veterans Affairs Co-operative Study
10. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: An open pilot study
11. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab
12. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial
13. The role of TNF in health and disease
14. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody
15. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group
16. Anti-TNF-alpha chimeric antibody (cA2) is effective in the treatment of the fistulae of Crohn's disease: A multicenter, randomized, double-blind, placebo-controlled study
17. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumour necrosis factor α
18. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis
19. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
20. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised Phase III trial
21. Long-term safety of infliximab and prevention of joint damage in patients with rheumatoid arthritis: Results of the attract trial
22. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-7c fusion protein
23. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial
24. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
25. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis
26. Crohn's disease associated with spondyloarthropathy: Effect of TNF-α blockade (infliximab) on the articular symptoms
27. Successful treatment of psoriatic arthritis with infliximab in a MRI controlled study
28. Anti-TNF-a restores the T cell cytokine balance in spondyloarthropathy
29. Immunomodulatory effects of anti-TNF-a therapy on synovium in spondyloarthropathy
30. T cell cytokines in gut mucosa of patients with spondyloarthropathy reflect immune alterations in Crohn's disease
31. Evidence for a different cytokine secretion pattern of peripheral blood mononuclear cells of HLA B27+ patients with ankylosing spondylitis and HLA B27+ healthy controls compared to HLA B27-negative controls
32. Differential Th1/Th2 cytokine patterns in chronic arthritis: Interferon γ is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies
33. The elevated ratio of interferon gamma-/interleukin-4-positive T cells found in synovial fluid and synovial membrane of rheumatoid arthritis patients can be changed by interleukin-4 but not by interleukin-10 or factor beta
34. Production, tissue distribution and function of IL-10 in psoriatic synovium
35. Crucial role of interleukin-10/interleukin-12 balance in the regulation of the Type 2 T helper cytokine response in reactive arthritis
36. IL-10 plasma levels correlate with disease activity in spondyloarthropathy
37. Clinical and laboratory improvement in ankylosing spondylitis after treatment with etanercept - A case report
38. Inflammatory bowel disease
39. Arthritis accompanying ulcerative colitis
40. Opportunities for immune modulation in the spondyloarthropathies with special reference to gut inflammation
41. Interleukin-10-deficient mice develop chronic enterocolitis
42. Anti-inflammatory effect of interleukin-10 in rabbit immune complex-induced colitis
43. Multiple doses of inrevenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group
44. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10
45. Beta2 integrin/ICAM expression in Crohn's disease
46. LFA-1 subunit expression in ulcerative colitis patients
47. Inhibition of endothelial cell-leukocyte adhesion molecule expression with antisense oligonucleotides
48. A placebo-controlled trial of ICAM-1 antisense ologinucleotide in the treatment of Crohn's disease
49. Expression and function of the MadCAM-1 receptor on human leukocytes
50. Enrichment of T cells carrying beta7 integrins in inflamed synovial tissue from patients with early spondyloarthropathy, compared to rheumatoid arthritis
51. Attenuation of colitis in the cotton-top tamarin by anti-α4 integrin monoclonal antibody
52. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha4beta7
53. Experimental immunization with anti-rheumatic bacterial extract OM-89 induces T cell responses to heat shock protein (hsp) 60 and hsp70; modulation of peripheral immunological tolerance as its possible mode of of rheumatoid arthritis
54. A 6-month randomized dose range study of OM-8980 in rheumatoid arthritis
55. OM8980 and D-penicillamine in the treatment of rheumatoid arthritis. A 12-month double-blind randomized study
56. Double-blind, placebo-controlled study of OM-8980 in rheumatoid arthritis
57. A double-blind multicentre study of OM-8980 and auranofin in rheumatoid arthritis
58. The effect of Subreum (OM8980) on the peripheral manifestations in spondyloarthropathy patients